Clinically Amyopathic Dermatomyositis: Epidemiology, Clinical Presentation, Pathophysiology, Treatment, and Prognosis: A Systematic Review
Rheumatology and Therapy · 2026-08 · 13 (4) · 997-1053
DOI: 10.1007/s40744-026-00863-0 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Rheumatology and Therapy, online erschienen am 16.06.2026. Verfasst von Jucier Gonçalves Júnior und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Medicina, Universidade Federal do Cariri (UFCA), R. Major Sampaio, 574, Alto Rosário, Barbalha, CE, 63180-000, Brazil. juciergjunior@hot…. Die Arbeit nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CAPES.
Abstract (Originalsprache)
Introduction
We conducted a systematic review on the epidemiology, clinical presentation, pathophysiology, treatment, and prognosis of clinically amyopathic dermatomyositis (CADM).
Methods
A qualitative systematic review was performed from October 1988 to January 2026 according to PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines, using seven electronic databases: PubMed, Web of Science, EMBASE, Virtual Health Library, PsycInfo, Scopus, and the Cochrane Library. Studies were eligible if at least one combination of search terms appeared in the title, were written in English, Portuguese, or Spanish, and addressed the epidemiology, pathogenesis, diagnosis, or treatment of CADM. Systematic reviews, theses, dissertations, letters, editorials, studies with unclear methodology, and articles addressing classic or paraneoplastic dermatomyositis were excluded.
Results
A total of 106 studies comprising 816 patients were included. CADM is more frequent among females and most prevalent in the fifth and sixth decades of life. The most common cutaneous findings were Gottron’s signs, heliotrope rash, and the V-neck sign. Interstitial lung disease (ILD) was the most frequent extracutaneous, extramuscular manifestation. Elevated ferritin, lactate dehydrogenase (LDH), and C-reactive protein (CRP) levels were common. The most frequent autoantibodies were anti-MDA-5 (Anti-Melanoma Differentiation-Associated gene 5) and anti-Ro-52. Treatment most often combined pulse glucocorticoids with human immunoglobulin, cyclophosphamide, rituximab, or cyclosporine. Poorer prognosis was associated with higher ferritin, CRP, and LDH levels, and with the presence of ILD.
Conclusions
CADM is a serious, complex disease with a distinct clinical and serological profile, requiring further conceptual refinement and multicenter studies to better characterize this DM phenotype.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculdade de Medicina, Universidade Federal do Cariri (UFCA), R. Major Sampaio, 574, Alto Rosário, Barbalha, CE, 63180-000, Brazil. juciergjunior@hotmail.com.
- Faculdade de Medicina, Universidade Regional do Cariri (URCA), Crato, CE, Brazil. juciergjunior@hotmail.com.
- Faculdade de Medicina, Universidade Federal do Cariri (UFCA), R. Major Sampaio, 574, Alto Rosário, Barbalha, CE, 63180-000, Brazil.
- Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil.
Förderung
- CAPES
Zitieren
APA
Gonçalves Júnior, J., Dos Santos, J. I. A., & Shinjo, S. K. (2026). Clinically Amyopathic Dermatomyositis: Epidemiology, Clinical Presentation, Pathophysiology, Treatment, and Prognosis: A Systematic Review. Rheumatology and Therapy, 13(4), 997-1053. https://doi.org/10.1007/s40744-026-00863-0
Vancouver
Gonçalves Júnior J, Dos Santos JIA, Shinjo SK. Clinically Amyopathic Dermatomyositis: Epidemiology, Clinical Presentation, Pathophysiology, Treatment, and Prognosis: A Systematic Review. Rheumatology and Therapy. 2026;13(4):997-1053. doi:10.1007/s40744-026-00863-0
BibTeX
@article{GonalvesJnior2026,
author = {Gonçalves Júnior, Jucier and Dos Santos, Jamily Izabel Alves and Shinjo, Samuel Katsuyuki},
title = {Clinically Amyopathic Dermatomyositis: Epidemiology, Clinical Presentation, Pathophysiology, Treatment, and Prognosis: A Systematic Review},
journal = {Rheumatology and Therapy},
year = {2026},
volume = {13},
number = {4},
pages = {997--1053},
doi = {10.1007/s40744-026-00863-0}
}
EUVIMED